Overview
Henry Gosebruch joined Galapagos as CEO and member of the Board of Directors on 12 May 2025, taking over from Paul Stoffels during the company's strategic refocus on small-molecule and biologics discovery. Before Galapagos, he served as President and CEO of Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on neuroscience. Earlier in his career he was Executive Vice President and Chief Strategy Officer at AbbVie, where he led corporate strategy, business development and M&A.
Career history
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.